Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Andrew Meads
Observed names:
A Meads,
A. Meads,
Andrew John Dennis Meads
Institution:
UroGen Pharma Ltd. (United States)
Observed institutions:
University of Auckland,
Morristown Medical Center,
Christchurch City Council,
Urology Associates,
Canterbury District Health Board,
UroGen Pharma Ltd. (United States),
Atlantic Health System,
University of Pennsylvania
show all 8
ORCID:
0000-0002-0847-1005
Observed ORCIDs:
0000-0002-0847-1005,
0009-0004-3106-6173
OpenAlex ID:
A5090212510
Effects and costs of real-time cardiac telerehabilitation: randomised controlled non-inferiority trial
2018
·
Ralph Maddison
, Jonathan Charles Rawstorn
, et al.
·
Heart
·
360
PDF
End Users Want Alternative Intervention Delivery Models: Usability and Acceptability of the REMOTE-CR Exercise-Based Cardiac Telerehabilitation Program
2018
·
Jonathan C. Rawstorn
, Nicholas Gant
, et al.
·
Archives of Physical Medicine and Rehabilitation
·
71
Remotely Delivered Exercise-Based Cardiac Rehabilitation: Design and Content Development of a Novel mHealth Platform
2016
·
Jonathan C Rawstorn
, Nicholas Gant
, et al.
·
JMIR mhealth and uhealth
·
66
MedBloc: A Blockchain-Based Secure EHR System for Sharing and Accessing Medical Data
2019
·
Jack Huang
, Yuan Wei Qi
, et al.
·
IEEE International Conference on Trust, Security and Privacy in Computing and Communications (TrustCom)
·
64
Push Notification Mechanisms for Pervasive Smartphone Applications
2014
·
Ian Warren
, Andrew Meads
, et al.
·
IEEE Pervasive Computing
·
60
Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS)
2023
·
Sandip M. Prasad
, William C. Huang
, et al.
·
The Journal of Urology
·
57
Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION)
2024
·
Sandip M. Prasad
, Dimitar Shishkov
, et al.
·
The Journal of Urology
·
55
Mobile Service Provisioning Middleware for Multihomed Devices
2009
·
Andrew Meads
, Adam Roughton
, et al.
·
IEEE International Conference on Wireless and Mobile Computing, Networking and Communications (WiMob)
·
30
GitHub in the Classroom: Lessons Learnt
2022
·
Yu-Cheng Tu
, Valerio Terragni
, et al.
·
Australasian Computing Education Conference
·
29
Skin surface temperature: a possible new outcome measure for skin and soft tissue infection.
2013
·
Michael Montalto
, Fletcher Davies
, et al.
·
PubMed
·
24
Sharing medical data using a blockchain‐based secure EHR system for New Zealand
2022
·
Jack Huang
, Yuan Wei Qi
, et al.
·
IET Blockchain
·
21
PDF
An Experience Report on a Boot-Camp Style Programming Course
2018
·
Yu-Cheng Tu
, Gillian Dobbie
, et al.
·
ACM Technical Symposium on Computer Science Education (SIGCSE)
·
20
Reducing hospital admissions for COPD: perspectives following the Christchurch Earthquake
2018
·
Michael Epton
, Carol Limber
, et al.
·
BMJ Open Respiratory Research
·
18
PDF
Behavior Change for Youth Drivers: Design and Development of a Smartphone-Based App (BackPocketDriver)
2018
·
Ian Warren
, Andrew Meads
, et al.
·
JMIR Formative Research
·
12
Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma With UGN-101, a Mitomycin Reverse Thermal Gel
2024
·
Phillip M. Pierorazio
, Nir Kleinmann
, et al.
·
The Journal of Urology
·
11
PDF
Moving a Bootcamp-Style Computer Science Programme Online: An Experience Report
2023
·
Andrew Meads
, Yu-Cheng Tu
, et al.
·
ACM Technical Symposium on Computer Science Education (SIGCSE)
·
6
PDF
OdinTools--Model-Driven Development of Intelligent Mobile Services
2011
·
Andrew Meads
, Ian Warren
·
IEEE International Conference on Services Computing
·
5
Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer With UGN-102: Outcomes From the 5-Year Long-Term Extension Study of the Single-Arm, Phase 2b Optima II Study
2025
·
Neal D. Shore
, K. Kent Chevli
, et al.
·
Clinical Genitourinary Cancer
·
4
PDF
Parallel computing for smart power oscillation monitoring using synchrophasor measurements
2010
·
Jimmy C.-H Peng
, A Meads
, et al.
·
IEEE Region 10 Conference (TENCON)
·
4
A Holistic Approach to Mobile Service Provisioning
2009
·
Andrew John Dennis Meads
·
IEEE/ACM International Conference on Automated Software Engineering (ASE)
·
4
Extending mobile service middleware with support for context-aware service processing
2010
·
A Meads
, I Warren
·
IEEE Region 10 Conference (TENCON)
·
3
UGN-102 for Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION Trial
2026
·
Sandip M. Prasad
, Dimitar Shishkov
, et al.
·
The Journal of Urology
·
2
PDF
Duration of response (DoR) following treatment with UGN-102 in patients with recurrent, low-grade, intermediate-risk, non-muscle invasive, bladder cancer: 18-month DoR data from the phase 3 ENVISION trial.
2025
·
Sandip M. Prasad
, Nikola V Mihaylov
, et al.
·
Journal of Clinical Oncology
·
2
PDF
Pd12-01 Treatment of Recurrent Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer With Ugn-102: Ongoing Results From a Single-arm, Open-label, Phase 3 Trial (envision)
2025
·
Sandip M. Prasad
, Dimitar Shishkov
, et al.
·
The Journal of Urology
·
2
PDF
Mp15-05 Treatment of Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer With Ugn-102: Long-term Outcomes of the Optima Ii Study
2025
·
Neal D. Shore
, K. Kent Chevli
, et al.
·
The Journal of Urology
·
2
PDF
Show more works
View as search
Works count:
50
Citation count:
946
H-index:
13
I10-index:
15
Year
Topic
Type